iNt Therapeutics Announces Interim Results of Phase 1 Clinical Trial in Australia for Osteoarthritis Pain Treatment at German Conference

[Asia Economy Reporter Lee Gwan-joo] Daewoong Pharmaceutical's new drug development specialist subsidiary iN Therapeutics announced on the 11th that it presented the interim results of the Phase 1 clinical trial in Australia for the non-opioid osteoarthritis pain treatment new drug candidate 'iN1011-N17' at the 'International Osteoarthritis Research Society International (OARSI) 2022 World Congress' held in Berlin, Germany.

The International Osteoarthritis Research Society International is one of the most influential international academic conferences in the field of orthopedics, and the abstract presented by iN Therapeutics was selected by the OARSI program committee and disclosed as a poster.

The new drug candidate iN1011-N17, developed by iN Therapeutics, is a non-opioid osteoarthritis pain treatment that demonstrated superior efficacy in preclinical studies compared to commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) or the opioid analgesic tramadol.

The Phase 1 clinical trial in Australia (single ascending dose study) presented at this conference was a randomized, double-blind, placebo- and active-controlled Phase 1 study, evaluating safety, tolerability, and pharmacokinetic characteristics after oral administration of the new drug candidate iN1011-N17 to 104 healthy volunteers.

iN Therapeutics explained that through this Phase 1 clinical trial, it secured key drug exposure data that can determine the dosing regimen in future clinical trials and confirmed the safety, tolerability, and pharmacokinetic superiority of the new drug candidate iN1011-N17.

Jong-duk Park, CEO of iN Therapeutics, said, “We are pleased to present the clinical utility and safety of the new drug candidate at an international academic conference,” and added, “Having secured safety and key drug exposure data through recent clinical results, we expect positive outcomes in future clinical trials.”

This content was produced with the assistance of AI translation services.